Your Health, We Care
Ibrutinib is also used to treat chronic lymphocytic leukemia/small lymphocytic lymphoma. Multiple international Phase II/III trials and Asia Pacific Phase III studies have evaluated the safety and efficacy of Ibrutinib in treating these diseases.
The results showed that Ibrutinib can significantly reduce the risk of death or progression in patients. Ibrutinib, as an important BTK inhibitor drug, has shown potential in the treatment of lymphoma.
